{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T22:42:03Z","timestamp":1720564923787},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.mehy.2017.05.026","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T17:48:44Z","timestamp":1496080124000},"page":"78-79","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Infections caused by resistant organisms: Could organic arsenic compounds be an effective treatment?"],"prefix":"10.1016","volume":"104","author":[{"given":"Victor D.","family":"Warner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert H.","family":"Soloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2017.05.026_b0005","series-title":"Organic Arsenical Compounds","first-page":"504","author":"Raiziss","year":"1923"},{"key":"10.1016\/j.mehy.2017.05.026_b0010","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/anie.200461471","article-title":"The composition of Ehrlich's Salvarsan: resolution of a century-old debate","volume":"44","author":"Lloyd","year":"2005","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.mehy.2017.05.026_b0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/ml2000092","article-title":"A platform for the detection of trypanosomes via selective small molecule recognition","volume":"2","author":"Beaulieu","year":"2011","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.mehy.2017.05.026_b0020","series-title":"The Specificity of Serological Reactions","author":"Landsteiner","year":"1945"},{"key":"10.1016\/j.mehy.2017.05.026_b0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4049\/jimmunol.107.2.353","article-title":"Antigen recognition and the immune response: the capacity of l-tyrosine-azobenzenearsonate to serve as a carrier for a macromolecular hapten","volume":"107","author":"Alkan","year":"1971","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2017.05.026_b0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/eji.1830030304","article-title":"The specificity of cellular immunity: studies in guinea pigs using defined tetrapeptides containing p-azobenzenearsonate-l-tyrosine","volume":"3","author":"Becker","year":"1973","journal-title":"Eur J lmmunol"},{"key":"10.1016\/j.mehy.2017.05.026_b0035","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4049\/jimmunol.104.4.874","article-title":"The specificity of tolerance induction in delayed hypersensitivity","volume":"104","author":"Goldman","year":"1970","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2017.05.026_b0040","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/0008-8749(82)90275-1","article-title":"The specificity of delayed hypersensitivity to ABA-tyr-pulsed and ABA- coupled macrophages","volume":"71","author":"Bhan","year":"1982","journal-title":"Cell Immunol"},{"key":"10.1016\/j.mehy.2017.05.026_b0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3181\/00379727-154-39654","article-title":"Hapten-specific response to a new arsenic acid conjugate, arsanil isothiocyanate","volume":"154","author":"Bhan","year":"1977","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.mehy.2017.05.026_b0050","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1021\/jm00255a002","article-title":"Chemoimmunotherapy of cancer. I","volume":"17","author":"Soloway","year":"1974","journal-title":"J Med Chem"},{"key":"10.1016\/j.mehy.2017.05.026_b0055","first-page":"3893","article-title":"Mechanisms of action of arsenic trioxide","volume":"62","author":"Miller","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.mehy.2017.05.026_b0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2010.04.001","article-title":"Arsenic trioxide-an old drug rediscovered","volume":"24","author":"Emadi","year":"2010","journal-title":"Blood Rev"},{"key":"10.1016\/j.mehy.2017.05.026_b0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2007.03.025","article-title":"Identification of arsenic\u00ad binding proteins in human breast cancer cells","author":"Zhang","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.mehy.2017.05.026_b0070","series-title":"Arsenic-based antineoplastic drugs and their mechanisms of action, metal\u00adbased drugs, vol. 1","first-page":"13","author":"Ralph","year":"2008"},{"key":"10.1016\/j.mehy.2017.05.026_b0075","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMcp1314325","article-title":"Lyme disease","volume":"370","author":"Shapiro","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2017.05.026_b0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nature12790","article-title":"Activated ClpP kills persisters and eradicates a chronic biofilm infection","volume":"503","author":"Conlon","year":"2013","journal-title":"Nature"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716307186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716307186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T11:45:21Z","timestamp":1719229521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987716307186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":16,"alternative-id":["S0306987716307186"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2017.05.026","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections caused by resistant organisms: Could organic arsenic compounds be an effective treatment?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2017.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}